The global Bioprocess Automation Software market, valued at $1.67 billion in 2025, is projected to grow to $6.19 billion by 2035 at a 14% CAGR. This growth is fueled by the increasing demand for personalized medicine, flexible manufacturing processes, and scalable biopharmaceutical production. The software enhances product quality, operational efficiency, and regulatory compliance by enabling real-time monitoring and data management. North America currently leads the market, while Asia-Pacific shows the fastest growth due to Industry 4.0 adoption.
The European Medicines Agency's CHMP has recommended marketing authorization for Novo Nordisk's Wegovy 7.2 mg single-dose pen for obesity treatment in the EU. Clinical trials showed an average weight loss of 20.7% in obese patients, with about one-th...
Eli Lilly's experimental obesity drug retatrutide achieved a 28% body weight loss over 80 weeks in a pivotal phase III trial, surpassing Novo Nordisk's leading treatments Wegovy and Ozempic. While retatrutide shows higher efficacy, it also has a high...
The European Medicines Agency's CHMP has recommended approval of Novo Nordisk's Wegovy pill (oral semaglutide) for weight management in the EU. The pill showed a mean weight loss of 16.6% in trials, comparable to the injectable version, and also redu...
